Balyasny Asset Management LLC Sage Therapeutics, Inc. Transaction History

Balyasny Asset Management LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $9.74 Million - $13.1 Million	-301,872 Reduced 89.93%	33,794 $1.32 Million
Q2 2022 Aug 15, 2022	BUY	$27.52 - $37.99 $8.71 Million - $12 Million	316,390 Added 1641.37%	335,666 $10.8 Million
Q1 2022 May 16, 2022	BUY	$30.71 - $45.71 $591,965 - $881,105	19,276 New	19,276 $638,000
Q4 2020 Feb 16, 2021	SELL	$58.41 - $89.06 $8.31 Million - $12.7 Million	-142,289 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$41.13 - $62.45 $5.85 Million - $8.89 Million	142,289 New	142,289 $8.7 Million

Q2 2020 Aug 14, 2020	SELL	$25.95 - $43.15 $494,036 - $821,489	-19,038 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$26.15 - $77.24 $3.49 Million - $10.3 Million	-133,467 Reduced 87.52%	19,038 $547,000
Q4 2019 Feb 14, 2020	BUY	$60.18 - $154.77 $4.63 Million - $11.9 Million	76,912 Added 101.74%	152,505 $11 Million
Q3 2018 Nov 14, 2018	BUY	$138.11 - $169.04 $8.47 Million - $10.4 Million	61,362 Added 431.19%	75,593 $10.7 Million
Q2 2018 Aug 14, 2018	SELL	$140.36 - $175.76 $31.4 Million - $39.4 Million	-223,900 Reduced 94.02%	14,231 $2.23 Million
Q1 2018 May 15, 2018	SELL	$152.15 - $192.33 $3.51 Million - $4.44 Million	-23,069 Reduced 8.83%	238,131 $38.4 Million
Q4 2017 Feb 14, 2018	SELL	$60.72 - $167.34 $5.99 Million - $16.5 Million	-98,602 Reduced 27.4%	261,200 $43 Million
Q3 2017 Nov 14, 2017	BUY	$61.4 - $88.52 $22.1 Million - $31.8 Million	359,802	359,802 $22.4 Million

222

52.7M

207K

191K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $641M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.